A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

• Main Authors: Xiaoniu Miao (Author), Yi Luo (Author), Xi Huang (Author), Suki M. Y. Lee (Author), Zhijun Yuan (Author), Yongzhou Tang (Author), Liandi Chen (Author), Chao Wang (Author), Fan Wu (Author), Yifeng Xu (Author), Wenchao Jiang (Author), Wei Gao (Author), Xuedong Song (Author), Yao Yan (Author), Tuling Pang (Author), Cheng Chen (Author), Yuefeng Zou (Author), Weihui Fu (Author), Liping Wan (Author), Javier Gilbert-Jaramillo (Author), Michael Knight (Author), Tiong Kit Tan (Author), Pramila Rijal (Author), Alain Townsend (Author), Joanne Sun (Author), Xiaolin Liu (Author), William James (Author), Andy Tsun (Author), Yingda Xu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combine...